We view continuous innovation as the most promising way to bring new medicines for unmet medical needs to the patient. Looking to the future, our long-standing expertise in medicinal chemistry and biotechnology have put us in an excellent position to exploit the huge potential of molecular medicine.
From precise diagnosis to targeted therapy
Together, a potent new drug and a blood test to guide its use can be a life changer for patients. Roche is a global leader in both sectors: the world’s biggest biopharmaceuticals company, the leading supplier of in vitro diagnostics and an innovator across major disease areas from cancer to virology.
Our business is science-driven. We are using our exceptional research and development capabilities to develop drugs, diagnostics and drug/diagnostic combinations to address some of medicine’s most pressing challenges.
Products with clinical benefits
Despite significant advances in modern medicine, social and economic factors make the need for innovative, new products in the diagnosis and treatment of disease greater than ever.
Roche’s resources are focused on two research-intensive businesses:
- pharmaceuticals and
Within these businesses, priority is placed in areas of significant unmet medical need where the expertise at Roche can make a difference. The goal is to develop new and improved drugs, diagnostic tests, and services offering significant benefits over existing options.
For this reason, Roche invests heavily in research and development – more than 8.4 billion Swiss francs in 2012 – and will continue to do so in future.